Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.65 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464597 | 0.89 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1ALOX5 | |
| SCHEMBL3464774 | 0.88 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1 | |
| SCHEMBL3464531 | 0.81 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1 | |
| SCHEMBL3465306 | 0.81 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1ALOX5 | |
| SCHEMBL5521618 | 0.79 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL3465442 | 0.77 | RAB9A (0.46) | HSP90AA1HSP90AB1 | |
| SCHEMBL5035437 | 0.76 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1 | |
| SCHEMBL3465067 | 0.76 | ALDH1A1 (0.38) | HSP90AA1HSP90AB1 | |
| SCHEMBL3464165 | 0.75 | HSP90B1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL5039069 | 0.72 | HSP90AA1 (0.86) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | claimed |
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2183221-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | Crystax Pharmaceuticals S.L. (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885ALOX5 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.